Tag Archives: drug pricing

The US Biotech Drug Pricing Challenge

by Tom Norton In the midst of the hue and cry last week over the public release of individual Medicare payments to physicians, I was surprised to read that one of Medicare’s most costly medical services is — ophthalmology.  According to the New York Times: “One of the most heavily reimbursed procedures — costing a […]
Posted in Biotech, Corporate Responsibility, Guest Blog, healthcare, Market Access, pricing, Strategy | Also tagged , , , , , , , | 1 Comment

The Sovaldi Case: Is American Biotech History About to Repeat Itself?

Recent Congressional investigations over the pricing scheme of Gilead’s much-heralded hepatitis C drug Sovaldi – and a decline in stocks across the biotech sector – rings a familiar bell, writes Tom Norton. Twenty years ago in May, US Senator Joe Lieberman carefully questioned biotech CEO Harry Penner of then Neurogen Corporation about why his company’s […]
Posted in Biotech, healthcare, leadership, Market Access, pricing, R&D, Sales, Strategy | Also tagged , , , , , , , , | 1 Comment

Casing Cancer: ASCO Launches New Series on State of the Disease

Despite its importance as a vital indicator of overall population health status, cancer suffers from an information deficit – particularly when considered from a global perspective. The American Society of Clinical Oncology [ASCO], the lead professional group in this space, is now working to rectify at least part of the gap with the launch of […]
Posted in healthcare, leadership, Market Access, pricing, R&D, Regulatory, Safety, Strategy | Also tagged , , , , | Leave a comment

Bringing New Rx Drugs to Market in 2014

by Tom Norton I did something today that I haven’t done in years: I checked out the US pharmaceutical R&D spend versus the rest of the world. Having known since the 80’s that the US owned this space, a quick look at the latest R&D figures confirmed my decades old understanding of the industry’s worldwide […]
Posted in Biotech, Corporate Responsibility, Emerging Markets, Europe, FDA, Global, Guest Blog, Market Access, pricing, Strategy | Also tagged , , , , , | 3 Comments

Battle Escalates over 340B Drug Pricing Program

What was once an obscure federal policy for providing low-cost drugs to safety-net hospitals has grown into a program that requires extensive discounting to one-third of the nation’s hospitals and health clinics. Pharma companies are pushing back, heightening tensions between “covered entities” that qualify for greatly reduced prices on medicines under 340B — and manufacturers […]
Posted in healthcare, pricing, Regulatory, Sales, Strategy | Also tagged , , , , , , , , , , , , , | Leave a comment
  • Categories

  • Meta